53981-23-0

Basic information

• Product Name: 2-AMINO-3-FLUOROPHENOL
• Synonyms: 6-Fluoro-2-hydroxyaniline;Phenol, 2-aMino-3-fluoro-;2-Fluoro-6-hydroxyaniline;2-AMINO-3-FLUOROPHENOL
• CAS NO: 53981-23-0
• Molecular Formula: C₆H₆FNO
• Molecular Weight: 127.12
• Product Categories: Fluorine series
• Mol File: 53981-23-0.mol

Chemical Properties

• Melting Point: 126-127°
• Boiling Point: 221.9°Cat760mmHg
• Flash Point: 88°C
• Appearance: /
• Density: 1.347g/cm³
• Vapor Pressure: 0.0704mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.76±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-3-FLUOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-3-FLUOROPHENOL(53981-23-0)
• EPA Substance Registry System: 2-AMINO-3-FLUOROPHENOL(53981-23-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• RIDADR: 2512
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 53981-23-0(Hazardous Substances Data)

Usage

Uses

2-Amino-3-fluorophenol is a reagent that is used in the preparation of benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN) deficient cancers.

InChI:InChI=1/C6H6FNO/c7-4-2-1-3-5(9)6(4)8/h1-3,9H,8H2

Upstream product

• 127682-43-3 O-(3-fluorophenyl)hydroxylamine 
• 385-01-3 2-nitro-3-fluorophenol 
• 19064-24-5 2,6-difluoro-1-nitrobenzene 
• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 384346-28-5 N-(2-fluoro-6-hydroxyphenyl)acetamide 
• 18063-03-1 2,6-difluorobenzamide 
• 160564-65-8 2-(benzyloxy)-6-fluoroaniline 

Downstream Products

• 384346-28-5 N-(2-fluoro-6-hydroxyphenyl)acetamide 
• 1058225-29-8 2-acetamido-3-fluorophenyl acetate 
• 590422-12-1 4-fluoro-1,3-benzoxazol-2(3H)-one 
• 384346-21-8 N-[2-Fluoro-6-(2-oxiranylmethoxy)phenyl]acetamide 
• 1252554-73-6 4-bromo-2,6-difluoro-N-(2-fluoro-6-hydroxyphenyl)benzamide 
• 186309-73-9 2-amino-5-bromo-3-fluorophenol 

Relevant articles and documents

Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876

Studies directed at developing a broadly acting non-nucleoside inhibitor of HCV NS5B led to the discovery of a novel structural class of 5-aryl benzofurans that simultaneously interact with both the palm I and palm II binding regions. An initial candidate was potent in vitro against HCV GT1a and GT1b replicons, and induced multi-log reductions in HCV viral load when orally dosed to chronic GT1 infected chimpanzees. However, in vitro potency losses against clinically relevant GT1a variants prompted a further effort to develop compounds with sustained potency across a broader array of HCV genotypes and mutants. Ultimately, a biology and medicinal chemistry collaboration led to the discovery of the development candidate MK-8876. MK-8876 demonstrated a pan-genotypic potency profile and maintained potency against clinically relevant mutants. It demonstrated moderate bioavailability in rats and dogs, but showed low plasma clearance characteristics consistent with once-daily dosing. Herein we describe the efforts which led to the discovery of MK-8876, which advanced into Phase 1 monotherapy studies for evaluation and characterization as a component of an all-oral direct-acting drug regimen for the treatment of chronic HCV infection.

INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE

Compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and /or viral production in a cell-based system. Wherein Z, R30, R40, R50 and R60 of compounds of formula (I) are herein defined as in the description.

N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, m and n have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful in the treatment of diseases and conditions associated with inflammation.

The neighboring group effect of fluorine in the tritium labeling of organic substrates with [Cp*(PMe3)IrMe(CH2Cl 2)]+ [BArf]-, a cationic iridium(III) complex

The cationic Ir(III) complex, [Cp*(PMe3)IrMe(CH 2Cl2)][BArf] (1, Cp* = η5-C5Me5, BArf = MeB(C 6F5)3), has been shown to be a useful reagent in the tritium and deuterium labeling of organic substrates. During a recent reaction of 1 with a fluorinated molecule, we observed an unusually high incorporation of tritium ortho to the aromatic fluorines. To probe whether this was an isolated incident or a more general phenomenon, we have investigated the application of 1 towards the tritiation of simple fluorinated organic substrates. Our results indicate that aromatic fluorine indeed does exhibit a neighboring group effect in terms of directing ortho H/T exchange. The directing influence appears to be at least as strong as the hydroxyl moiety reported in previous works. Copyright

N-aryl-2-oxazolidinone-5-carboxamides and their derivatives

The present invention provides antibacterial agents having the formulae I, II, and III described herein.

N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS

Compounds of formula B-C-A-CO-NH-R1, wherein A is structure i, ii or iii: formulae (I), (II), (III). C is optionally substituted aryl or heteroaryl, and B is a specified cyclic moiety, or C and B together are a heterobicyclic moiety, are useful as antibacterial agents.

Novel compounds

The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

IL-8 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine Interleukin-8 (IL-8).

IL-8 RECEPTOR ANTAGONISTS

This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).